NCT03626662View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a)

PHASE1CompletedINTERVENTIONAL
Enrollment

79

Participants

Timeline

Start Date

July 30, 2018

Primary Completion Date

April 18, 2023

Study Completion Date

April 18, 2023

Conditions
Cardiovascular Disease
Interventions
DRUG

AMG 890

Ascending Single Doses of AMG 890

DRUG

Placebo

Calculated volume to match experimental drug.

Trial Locations (9)

5000

Clinical Medical and Analytical eXellence CMAX, Adelaide

6009

Linear Clinical Research Limited, Nedlands

10016

New York University, New York

32216

Jacksonville Center for Clinical Research, Jacksonville

33143

QPS Miami Research Associates, South Miami

33434

Excel Medical Clinical Trials, Boca Raton

45227

Medpace Inc, Cincinnati

66160

University of Kansas Medical Center, Kansas City

92780

Orange County Research Center, Tustin

Sponsors

Lead Sponsor

Amgen
All Listed Sponsors
lead

Amgen

INDUSTRY

NCT03626662 - Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of AMG 890 in Subjects With Elevated Plasma Lipoprotein(a) | Biotech Hunter | Biotech Hunter